GSK Press Releases - EIN Presswire - Press Release Distribution Service

Published on February 26, 2013 - 12:03 GMT

GSK response to news article in The Guardian on UK legal proceedings related to Avandia (rosiglitazone)

30 January 2013 Responding to a news article in The Guardian this morning on UK legal proceedings related toour type 2 diabetes medicine Avandia (rosiglitazone), we would like to make the following points: We have every sympathy for people with health …

Distribution channels: Companies

Published on February 26, 2013 - 12:03 GMT

GlaxoSmithKline starts Phase III study to test combined BRAF/MEK inhibition in patients with BRAF positive melanoma following ...

Issued: Friday 1st February 2013, London UK GlaxoSmithKline plc. today announced the start of COMBI-AD, a Phase III study evaluating the combination of dabrafenib, its BRAF inhibitor and trametinib, its MEK inhibitor as adjuvant therapy for melanoma. This …

Distribution channels: Companies

Published on February 26, 2013 - 12:03 GMT

GSK increases stake in its publicly-listed Consumer Healthcare subsidiary in India to 72.5 per cent

Issued: Tuesday 5 February 2013, London UK – LSE Announcement GlaxoSmithKline plc (LSE: GSK) announced today that, pursuant to the voluntary open offer undertaken by its subsidiary, GlaxoSmithKline Pte. Ltd, GSK has successfully increased its stake in …

Distribution channels: Companies

Published on February 26, 2013 - 12:03 GMT

GSK announces support for AllTrials campaign for clinical data transparency

Issued: Tuesday 5 February 2013, London UK GSK today further demonstrated its commitment to clinical trial transparency by announcing its support for the AllTrials campaign. The campaign is calling for registration of clinical trials and the disclosure of …

Distribution channels: Companies

Published on February 26, 2013 - 12:03 GMT

Results announcement for the fourth quarter 2012

Issued Wednesday 6 February 2012 - LSE announcement GSK delivers 2012 core EPS of 112.7p and returns £6.3 billion to shareholders Group sales -1%; flat excluding disposals of OTC brands Successful RD delivery: 6 new drugs filed since start of 2012 Phase …

Distribution channels: Companies

Published on July 16, 2012 - 14:12 GMT

GSK to acquire Human Genome Sciences for US$14.25 per share in cash

Issued: Monday 16 July 2012, London UK GSK to acquire full ownership of BENLYSTA®, albiglutide and darapladib. Acquisition will be accretive to GSK core earnings in 2013. Tender offer amended to US$14.25 per share and extended until 27 July 2012 …

Distribution channels: Companies

Published on July 16, 2012 - 06:10 GMT

GlaxoSmithKline celebrates its role in supporting the biggest anti-doping operation in the history of the Olympic Games

Issued: Monday 16 July 2012, London, UK GSK launches new advertising campaign to highlight the role that science will play in keeping the London 2012 Games clean GSK today marks its role as Official Laboratory Services Provider for the London 2012 …

Distribution channels: Companies

Published on July 13, 2012 - 11:12 GMT

GSK and Theravance announce regulatory submissions for FF/VI in the US and Europe

Issued: Friday 13 July 2012, London UK Relvar™ and Breo™ proposed as brand names for FF/VI in EU and US; new dry powder inhaler proposed to be named Ellipta™ GlaxoSmithKline plc (GSK) and Theravance, Inc. (NASDAQ: THRX) today announced the submission of …

Distribution channels: Companies

Published on July 12, 2012 - 15:10 GMT

US Regulatory Update – Tykerb® (lapatinib)

Issued: Thursday 12 July 2012, London UK GlaxoSmithKline plc announced today that it has withdrawn a supplemental New Drug Application to the US Food and Drug Administration (FDA) for Tykerb (lapatinib) in combination with trastuzumab for the treatment …

Distribution channels: Companies

Published on July 11, 2012 - 16:10 GMT

GSK announces positive data from Harmony 8 and completion of clinical registration package for albiglutide in type 2 diabetes

Issued: Wednesday 11 July 2012, London UK GlaxoSmithKline (GSK) today announced that data have been received from the Phase III Harmony 8 study and from the event driven meta-analysis for assessment of cardiovascular safety conducted across the …

Distribution channels: Companies

Published on July 11, 2012 - 06:10 GMT

Shionogi-ViiV Healthcare announces positive initial data from phase III study of dolutegravir-based regimen vs Atripla in HIV

Issued: Wednesday 11 July 2012, London UK Shionogi-ViiV Healthcare LLC today announced that initial results have been received from the Phase III SINGLE (ING114467) study of the investigational integrase inhibitor dolutegravir in treatment-naïve adults …

Distribution channels: Companies

Published on July 2, 2012 - 15:11 GMT

GlaxoSmithKline concludes previously announced agreement in principle to resolve multiple investigations with US Government and ...

Issued: Monday 02 July 2012, London UK & Philadelphia, US Final settlement of $3bn covered by existing legal provisions announced in November 2011. Fundamental changes to US compliance, marketing and selling procedures implemented in recent years. …

Distribution channels: Companies

Published on July 2, 2012 - 07:10 GMT

GSK and Theravance announce positive results from four pivotal phase III studies for once-daily LAMA/LABA (UMEC/VI) in COPD

Issued: Monday 02 July 2012, London UK and South San Francisco, CA Headline results from the pivotal efficacy studies support intention to commence global filings for UMEC/VI from end of 2012, ahead of schedule GlaxoSmithKline plc (LSE: GSK) and …

Distribution channels: Companies

Published on June 29, 2012 - 19:11 GMT

GSK sets 20 July for expiration of tender offer to acquire Human Genome Sciences

Issued: Friday 29 June 2012, London UK - Expiration is after HGS process bid deadline of 16 July - Enables HGS shareholders to evaluate outcome of process and GSK’s offer GlaxoSmithKline plc (LSE: GSK) today announced it has extended its tender …

Distribution channels: Companies

Published on June 15, 2012 - 14:10 GMT

GSK continues with tender offer to acquire all outstanding shares of Human Genome Sciences

Issued: Friday 15 June 2012, London, UK GlaxoSmithKline plc (LSE: GSK) today confirmed that it has received a renewed invitation from Human Genome Sciences’ (NASDAQ: HGSI) to participate in its strategic alternatives review process which started in …

Distribution channels: Companies

Published on June 14, 2012 - 22:11 GMT

GSK receives FDA approval for MenHibrix

Issued: Thursday 14 June 2012, Philadelphia, Pennsylvania First combination vaccine to help prevent meningococcal serogroups C and Y and Hib disease GlaxoSmithKline plc announced today that the U.S. Food and Drug Administration (FDA) has approved the …

Distribution channels: Companies

Published on June 11, 2012 - 22:10 GMT

Stiefel signs worldwide acquisition and license agreement for Toctino®

Issued: Monday 11 June 2012, London UK – [For non US media only] Stiefel, a GSK company, today announced that it has entered into a worldwide agreement to acquire Toctino (alitretinoin) from Basilea Pharmaceutica Ltd. (Basilea). Toctino is a once-daily …

Distribution channels: Companies

Published on June 9, 2012 - 18:10 GMT

GSK announces new 52-week data from phase III study of once-weekly albiglutide in type 2 diabetes

Issued: Saturday 09 June 2012, London UK Detailed 52 and 32-week data from the first two Phase III studies of the investigational once-weekly glucagon-like peptide-1 (GLP-1) receptor agonist presented at ADA Detailed findings from a Phase III study …

Distribution channels: Companies

Published on June 8, 2012 - 13:10 GMT

GSK extends tender offer for all outstanding shares of Human Genome Sciences

Issued: Friday 08 June 2012, London UK GlaxoSmithKline plc (LSE: GSK) today announced it has extended its tender offer to acquire all of the outstanding shares of Human Genome Sciences (NASDAQ: HGSI) for US$13.00 per share in cash to 5:00 pm New York …

Distribution channels: Companies

Published on June 7, 2012 - 11:10 GMT

GSK and XenoPort receive FDA approval for Horizant® for postherpetic neuralgia

Issued: Thursday 07 June 2012, London UK and NC & Santa Clara, CA GlaxoSmithKline plc (GSK) and XenoPort, Inc. (Nasdaq: XNPT) announced today that the United States (US) Food and Drug Administration (FDA) has approved Horizant ® (gabapentin …

Distribution channels: Companies